Skip to main content

Table 2 Percentages of total CD34+ cells and CD34+ fractions

From: Correlation between CD117+ myeloma plasma cells and hematopoietic progenitor cells in different categories of patients

 

Tot CD34+

CD34 + CD19-

CD34 + CD19+

Ratio

Control

1.17

85.74

14.26

6.01

 

(0.72–2.17)

(72.94–90.62)

(9.38–27.06)

(2.70–9.66)

MGUS

1.34

88.51

11.49

7.82

 

(0.30–2.46)

(82.58–97.99)

(2.01–17.42)

(4.74–48.75)

Complete

1.98

88.10

11.91

18.75

 

(0.45–8.26)

(24.18–98.75)

(1.25–75.97)

(0.32–79)

Therapy

1.28

73.12

26.88

2.73

 

(0.14–2.84)

(33.91–98.71)

(1.29–66.09)

(0.51–76.52)

New

1.26

87.11

12.90

6.77

 

(0.06–2.61)

(74.98–98.89)

(1.11–25.02)

(3–89.09)

Progressive

0.70

84.24

15.76

5.66

 

(0.22–0.87)

(75.73–94.83)

(5.17–24.27)

(3.12–18.34)

  1. Results are presented as median values (range)
  2. Tot CD34+, total CD34+ hematopoietic progenitor cells; CD34 + CD19-, fraction of CD34 + CD19- cells (out of total CD34+ cells); CD34 + CD19+, fraction of CD34 + CD19+ cells (out of total CD34+ cells); Ratio, CD34 + CD19-/CD34 + CD19+ cellular fraction ratio
  3. The Kruskal-Wallis statistic test with pairwise comparisons was used for this analysis (no significant results)